In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Gov. Hohcul announced part of Saint Rose campus will be turned into a workforce development hub as part of the ON RAMP initiative ...

Kathy Hochul has big plans for the former College of Saint Rose campus. Hochul wants to turn part of the former college into ...

Congratulations to Vivek Malik who was named a Regeneron Science Talent Search 2025 finalist. Vivek is a student at The ...